Is a lower dose of cetrorelix acetate effective for prevention of LH surge during controlled ovarian hyperstimulation?

Chen, Heng J.; Lin, Yu Hung; Hsieh, Bih Chwen; Seow, Kok-Min; Hwang, Jaeuk; Tzeng, Chii Ruey

doi:10.1007/s10815-006-9054-0

Cited by 13 publications

(8 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cetrorelix suppressed estrogen, progesterone, and testosterone levels in female rats (Horvath et al, ). Cetrorelix suppresses testosterone in postmenopausal women (Chantler, Gordon, Millan, & Panarelli, ; Pechstein et al, ) and estrogen levels in women undergoing controlled ovarian hyperstimulation (Buchter et al, ; Chen et al, ).…”

Section: Discussionmentioning

confidence: 99%

“…In premenopausal women, leuprolide and cetrorelix suppress LH and FSH levels (Larmore & Klein, 2000;Pechstein et al, 2000). Single dose administration of not only cetrorelix but also leuprolide reduces LH level in rats after 7 days of treatment (Chen et al, 2006;Murase et al, 2005). This may be due to continuous administration of GnRH-agonist-mediated downregulation of receptor and suppression of gonadotropin secretion (Magon, 2011).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Evaluation of ovarian and metabolic effects of GnRH modulators in two rat models of polycystic ovary syndrome

Patel¹,

Shah

2018

Molecular Reproduction Devel

View full text Add to dashboard Cite

Gonadotropin-releasing hormone (GnRH) modulators are widely used in numerous reproductive conditions including infertility. Several clinical studies showed mixed results regarding the efficacy of GnRH modulators in patients with polycystic ovary syndrome (PCOS). Along with this, few preclinical studies focus on the effect of GnRH modulators in PCOS-induced animals. Therefore, the present study was designed to study the effect of leuprolide and cetrorelix on hormonal, metabolic, and menstrual dysfunction PCOS rats. Prepubertal female rats were divided into four groups: Group I received a normal pellet diet and Groups II, III, and IV received 40% high-fat diet for 105 days. Similarly, adult female rats were divided into four groups: Group I received 1% carboxymethylcellulose (CMC) and Groups II, III, and IV received letrozole (1 mg/kg, per oral [p.o.] in 1% CMC) for 21 days. Thereafter, leuprolide (2.5 µg/rat, s.c.) and cetrorelix (10 µg/kg, subcutaneous [s.c.]) treatment were given to Group III and Group IV animals, respectively, for 21 days. Oral glucose tolerance test, lipid profile, fasting glucose, insulin, estrus cycle, hormonal profile, ovary weight, ovarian histopathological changes, and LHR and FSHR expressions were measured. Treatment with leuprolide and cetrorelix did not improve glucose intolerance, insulin level, insulin sensitivity indices, sex hormone levels, lipid profile, and estrus cycle. Only testosterone level, total cholesterol level, and follicular development were improved. Therefore, it was concluded that both leuprolide and cetrorelix showed improvement in follicular development, which could be helpful for improving fertility in PCOS.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Evaluation of ovarian and metabolic effects of GnRH modulators in two rat models of polycystic ovary syndrome

Patel¹,

Shah

2018

Molecular Reproduction Devel

View full text Add to dashboard Cite

show abstract

“…In other words, if the live birth rates were not affected, any protocols that use the least amount of GnRH antagonist would be less costly. Under the background of decreasing exposure to GnRH antagonist, Chen et al showed that a daily dose of 0.2 mg cetrorelix acetate was effective to prevent premature LH surge with comparable clinical pregnancies ( 29 ). Other researcher revealed that alternate-day administration of ganirelix was as effective as daily injections in preventing premature luteinization with similar clinical pregnancy rate ( 30 ).…”

Section: Discussionmentioning

confidence: 99%

Cessation of Gonadotropin-Releasing Hormone Antagonist on Triggering Day: An Alternative Method for Flexible Multiple-Dose Protocol

et al. 2009

View full text Add to dashboard Cite

This study was performed to analyze retrospectively outcomes of stimulated in vitro fertilization (IVF) cycles where the gonadotropin-releasing hormone (GnRH) antagonist was omitted on ovulation triggering day. A total of 92 consecutive IVF cycles were included in 65 women who are undergoing ovarian stimulation with recombinant FSH. A GnRH antagonist, cetrorelix 0.25 mg/day, was started when leading follicle reached 14 mm in diameter until the day of hCG administration (Group A, 66 cycles) or until the day before hCG administration (Group B, 26 cycles). The duration of ovarian stimulation, total dose of gonadotropins, serum estradiol levels on hCG administration day, and the number of oocytes retrieved were not significantly different between the two groups. The total dose of GnRH antagonist was significantly lower in Group B compared to Group A (2.7±0.8 vs. 3.2±0.9 ampoules). There was no premature luteinization in the subjects. The proportion of mature oocytes (71.4% vs. 61.7%) and fertilization rate of mature (86.3±19.7% vs. 71.8±31.7%) was significantly higher in Group B. There were no significant differences in embryo quality and clinical pregnancy rates. Our results suggest that cessation of the GnRH antagonist on the day of hCG administration during a flexible multiple-dose protocol could reduce the total dose of GnRH antagonist without compromising IVF results.

show abstract

“…The present study obtained LH a surge suppression using a novel GnRH-antagonist protocol with a lower dose of cetrorelix (0.125 mg) starting on the evening of Day 5 of ovarian stimulation, and increased to 0.250 mg once an appropriate follicular size was reached. In addition, the mean amount of cetrorelix administered per patient in this study, 0.9 mg, was less than the 1.0 mg used in one of the previous trials of 0.20 mg in a fixed scheme [11]. To the best of our knowledge, the treatment protocol in this study used the lowest dose of GnRH antagonist reported in clinical trials.…”

Section: Discussionmentioning

confidence: 60%

“…Previous studies demonstrated that a fixed scheme of 0.20 mg/day of cetrorelix was effective in preventing a premature LH surge regardless of follicular size [11,12]. The present study obtained LH a surge suppression using a novel GnRH‐antagonist protocol with a lower dose of cetrorelix (0.125 mg) starting on the evening of Day 5 of ovarian stimulation, and increased to 0.250 mg once an appropriate follicular size was reached.…”

Section: Discussionmentioning

confidence: 62%

Effect of a lower‐dose cetrorelix acetate protocol on in‐vitro fertilization outcome

Tzeng

Chen

Lin

et al. 2007

Intl J Gynecology & Obste

Self Cite

View full text Add to dashboard Cite

show abstract

Is a lower dose of cetrorelix acetate effective for prevention of LH surge during controlled ovarian hyperstimulation?

Abstract: This study demonstrates that a daily dose of cetrorelix 0.2 mg is able to prevent premature LH surge.

Cited by 13 publications

References 18 publications

Evaluation of ovarian and metabolic effects of GnRH modulators in two rat models of polycystic ovary syndrome

Evaluation of ovarian and metabolic effects of GnRH modulators in two rat models of polycystic ovary syndrome

Cessation of Gonadotropin-Releasing Hormone Antagonist on Triggering Day: An Alternative Method for Flexible Multiple-Dose Protocol

Effect of a lower‐dose cetrorelix acetate protocol on in‐vitro fertilization outcome

Contact Info

Product

Resources

About